This company listing is no longer active
La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
BioMarin Pharmaceutical Salute del bilancio
Salute finanziaria criteri di controllo 5/6
BioMarin Pharmaceutical has a total shareholder equity of $4.9B and total debt of $1.1B, which brings its debt-to-equity ratio to 22.2%. Its total assets and total liabilities are $6.8B and $1.9B respectively. BioMarin Pharmaceutical's EBIT is $120.0M making its interest coverage ratio -3.5. It has cash and short-term investments of $1.1B.
Informazioni chiave
22.2%
Rapporto debito/patrimonio netto
US$1.09b
Debito
Indice di copertura degli interessi | -3.5x |
Contanti | US$1.13b |
Patrimonio netto | US$4.90b |
Totale passività | US$1.86b |
Totale attività | US$6.76b |
Aggiornamenti recenti sulla salute finanziaria
Nessun aggiornamento
Recent updates
Analisi della posizione finanziaria
Passività a breve termine: BM8's short term assets ($3.0B) exceed its short term liabilities ($1.2B).
Passività a lungo termine: BM8's short term assets ($3.0B) exceed its long term liabilities ($698.0M).
Storia e analisi del rapporto debito/patrimonio netto
Livello di debito: BM8 has more cash than its total debt.
Riduzione del debito: BM8's debt to equity ratio has reduced from 41.2% to 22.2% over the past 5 years.
Copertura del debito: BM8's debt is not well covered by operating cash flow (12.8%).
Copertura degli interessi: BM8 earns more interest than it pays, so coverage of interest payments is not a concern.